Short-course hypofractionated proton beam therapy, incorporating 18F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trial.
Vora S, Pafundi D, Voss M, Buras M, Ashman J, Bendok B, Breen W, Hu L, Kizilbash S, Laack N, Liu W, Mahajan A, Mrugala M, Porter A, Ruff M, Sio T, Uhm J, Yang M, Brinkmann D, Brown P.
Vora S, et al. Among authors: hu l.
Lancet Oncol. 2024 Nov 18:S1470-2045(24)00585-0. doi: 10.1016/S1470-2045(24)00585-0. Online ahead of print.
Lancet Oncol. 2024.
PMID: 39571596